Dissolved and financials
CVR: 37134120
Previous names: RetiCare IVS
DKK -147,051
Gross profit
Net result: DKK -203,870
No owners listed
CVR · view owners
No management registered
CVR · view management
Dissolved
Ceased 25 September 2020
CVR · view overview
3 employees
CVR · 2020
Director role ended: Anders Rubinstein
CVR · 25/09/2020
View the full event history
RetiPharma IVS was a Danish company of the type Iværksætterselskab based in København N, founded in 2015. The company has been dissolved on 25 September 2020. The company was registered under the industry Anden teknisk rådgivning. The company was previously named RetiCare IVS. The company has 3 employees (2020). In 2018, the company reported a gross profit of DKK -147,051 and a net result of DKK -203,870 compared with DKK 0 the year before. Equity in the 2018 report amounted to DKK -190,437.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 201801/01/2018 – 31/12/2018 | - | -204 t. | 6.6 mio. | -190 t. | - | |
| 201701/01/2017 – 31/12/2017 | 0 | 0 | 1 | 1 | - |
Screen owners and management against the Danish FSA's official PEP lists
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorNo. RetiPharma IVS is registered in the Danish CVR register with the status Dissolved and ceased on 25 September 2020.
The CVR number of RetiPharma IVS is 37134120.
In 2018, RetiPharma IVS reported a gross profit of DKK -147,051.
RetiPharma IVS had 3 employees in 2020 according to the Danish CVR register.
RetiPharma IVS was founded on 10 September 2015.
RetiPharma IVS was registered under the industry Anden teknisk rådgivning (industry code 711290).
As of September 25, 2020, inforevision statsautoriseret revisionsaktieselskab has stepped down as auditor of RetiPharma IVS.
As of September 25, 2020, Anders Rubinstein has stepped down as liquidator of RetiPharma IVS.
On September 25, 2020, RetiPharma IVS exited liquidation.
RetiPharma IVS was dissolved on September 25, 2020.
As of November 22, 2019, Jørgen Axel Thorball has left the board of directors of RetiPharma IVS.
As of November 22, 2019, Casper Tind Hansen has left the board of directors of RetiPharma IVS.
As of November 22, 2019, David Paul Drucker Woldbye has left the board of directors of RetiPharma IVS.
As of November 22, 2019, Anders Rubinstein is registered as liquidator of RetiPharma IVS.
As of November 22, 2019, Line Hartvig has stepped down as adm. dir. of RetiPharma IVS.
As of November 22, 2019, Morten Albrechtsen has stepped down as chairman of RetiPharma IVS.
On November 22, 2019, RetiPharma IVS entered liquidation.
RetiPharma IVS has published its annual report for 2018. Gross profit came to DKK -147,051, and the net result was DKK -203,870.
As of June 1, 2019, Line Hartvig is registered as adm. dir. of RetiPharma IVS.
As of June 1, 2019, Henrik Vissing has stepped down as adm. dir. of RetiPharma IVS.
As of August 30, 2018, inforevision statsautoriseret revisionsaktieselskab has been appointed auditor of RetiPharma IVS.
RetiPharma IVS has published its annual report for 2017. Revenue came to DKK 0, and the net result was DKK 0.
As of April 16, 2018, Jørgen Axel Thorball has joined the board of directors of RetiPharma IVS.
As of April 16, 2018, Casper Tind Hansen has joined the board of directors of RetiPharma IVS.
As of April 16, 2018, David Paul Drucker Woldbye has joined the board of directors of RetiPharma IVS.
As of April 16, 2018, Henrik Vissing is registered as adm. dir. of RetiPharma IVS.
As of April 16, 2018, Morten Albrechtsen is registered as chairman of RetiPharma IVS.
As of April 16, 2018, Kristian Klemp has stepped down as director of RetiPharma IVS.
As of April 16, 2018, David Paul Drucker Woldbye has stepped down as adm. dir. of RetiPharma IVS.
On April 16, 2018, the company changed its name from RetiCare IVS to RetiPharma IVS.
RetiPharma IVS has published its interim report for the period September 10, 2015 to December 31, 2016.
As of October 4, 2017, Kristian Klemp is registered as director of RetiPharma IVS.
As of October 4, 2017, David Paul Drucker Woldbye is registered as adm. dir. of RetiPharma IVS.
As of August 31, 2017, Kristian Klemp has stepped down as director of RetiPharma IVS.
As of August 31, 2017, David Paul Drucker Woldbye has stepped down as adm. dir. of RetiPharma IVS.
As of September 10, 2015, Kristian Klemp is registered as director of RetiPharma IVS.
As of September 10, 2015, David Paul Drucker Woldbye is registered as adm. dir. of RetiPharma IVS.
RetiPharma IVS was founded on September 10, 2015.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Companies in the same industry and area
CVR 41962712
CVR 44008068
CVR 55352755
CVR 43523333
CVR 45983226
